Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Better Therapeutics, Inc. - Common Stock (NQ:BTTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Better Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
From Better Therapeutics Inc.
Via Business Wire
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
From Better Therapeutics Inc.
Via Business Wire
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
From Better Therapeutics
Via Business Wire
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
From Better Therapeutics, Inc.
Via Business Wire
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
From Better Therapeutics
Via Business Wire
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces $6.5MM Private Placement
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics to Participate in Two Upcoming Investor Conferences
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
From Better Therapeutics, Inc.
Via Business Wire
Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Better Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.